SCYNEXIS Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate UpdateGlobeNewsWire • 03/29/22
SCYNEXIS to Report Fourth Quarter and Full Year 2021 Financial Results and Provide a Business UpdateGlobeNewsWire • 03/24/22
SCYNEXIS Named to Fast Company's 2022 Top 50 List of the World's Most Innovative CompaniesGlobeNewsWire • 03/08/22
BREXAFEMME® (ibrexafungerp tablets) Added to Major National Formulary, Providing Access for Millions More Commercially Insured PatientsGlobeNewsWire • 12/20/21
European Medicines Agency Grants Orphan Medicinal Product Designation for SCYNEXIS' Innovative Antifungal Ibrexafungerp for the Indication of Invasive CandidiasisGlobeNewsWire • 12/15/21
BREXAFEMME® (Ibrexafungerp Tablets) Receives 2021 Popular Science Best of What's New Award in the Health CategoryGlobeNewsWire • 12/01/21
SCYNEXIS to Host Ibrexafungerp Hospital Pipeline Update Call and KOL Webcast for Investors on December 6GlobeNewsWire • 11/29/21
'The Big Short' investor Michael Burry revealed a stake in a tiny biotech company last week that has since soared 42%Business Insider • 11/22/21
'The Big Short' investor Michael Burry sold virtually all of his US stocks last quarter - but added 3 new positionsBusiness Insider • 11/15/21
SCYNEXIS, Inc. (SCYX) CEO Marco Taglietti on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/10/21
SCYNEXIS Reports Third Quarter 2021 Financial Results and Provides Corporate UpdateGlobeNewsWire • 11/10/21
SCYNEXIS Announces Successful Completion of Phase 1 Trial Evaluating Intravenous (IV) Formulation of IbrexafungerpGlobeNewsWire • 11/09/21
SCYNEXIS to Provide a Corporate Update and Report Third Quarter 2021 Financial Results on November 10GlobeNewsWire • 11/03/21
SCYNEXIS Pivotal Phase 3 VANISH-303 Trial Results Published in Clinical Infectious Diseases Demonstrate Significant Superiority of Ibrexafungerp Over Placebo for Treatment of Vaginal Yeast InfectionGlobeNewsWire • 10/21/21
SCYNEXIS to Present Pooled Data Analysis Results Demonstrating Consistent Efficacy and Safety Outcomes Across Two Phase 3 VANISH Clinical Trials of Oral Ibrexafungerp Therapy for Vaginal Yeast Infection at October Medical ConferencesGlobeNewsWire • 10/13/21
SCYNEXIS Announces Preclinical Data at the 10th Trends in Medical Mycology Meeting Supporting Potential of Ibrexafungerp to Treat MucormycosisGlobeNewsWire • 10/11/21
Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2021PRNewsWire • 09/30/21
SCYNEXIS Presents Interim Analysis from FURI at Virtual IDWeek 2021 Showing Favorable Therapeutic Response in Severe Hospital-Based Fungal Infections Treated with Oral IbrexafungerpGlobeNewsWire • 09/29/21
SCYNEXIS to Present Data on Oral Ibrexafungerp at IDWeek 2021 from Interim Analyses of Phase 3 FURI Clinical Trial Showing Therapeutic Response Rates in Patients with Mucocutaneous and Invasive Fungal InfectionsGlobeNewsWire • 09/23/21